Floatz Rating
CCC54/100
Confidence
Indicative
Sponsor
CHU de Quebec-Universite Laval
Modality
protein_peptide
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05896371CT.gov A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy | — | Not Yet Recruiting | — | — | — |
NCT07441837CT.gov Terbium 161 PSMA in Lutetium-177 PSMA Naive Patients | — | Not Yet Recruiting | — | — | — |
NCT06259123CT.gov Neoadjuvant PSMA-RLT in Oligometastatic PCa | — | Recruiting | — | — | — |
NCT06220188CT.gov PSMA-RLT in Biochemically Recurrent PCa | — | Recruiting | — | — | — |
NCT05893381CT.gov Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST) | — | Recruiting | — | — | — |
NCT05521412CT.gov EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T | — | Recruiting | — | — | — |
NCT05383079CT.gov Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT04886986CT.gov Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT06830408CT.gov Performance of 177Lu-PSMA-I&T for RLT in mCRPC - Prospective Multicenter Swiss Registry Study | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Psma I&T (this asset) | CHU de Quebec-Universite Laval | P2 | CCC · 54 |
| Avodart | Bay State Clinical Trials, Inc. | P4 | BBB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Propofol | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Degarelix | Bayer | P4 | BBB |
| Flotufolastat F 18 | Washington University School of Medicine | P4 | BB |
| AVOLVE | Masonic Cancer Center, University of Minnesota | P4 | BB |
| Estramustine | The University of Texas Health Science Center, Houston | P3 | BB |
| Pasireotide | RECORDATI GROUP | P4 | BB |
+42 more in the Prostate Cancer cohort
Other indications for Psma I&T
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Prostate Carcinoma | — | P3 | B · 60 |
| Nonpapillary Renal Cell Carcinoma | — | P1/2 | CCC · 52 |
| Metastatic Malignant Neoplasm | — | P1/2 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Psma I&T in Prostate Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/psma-it-prostate-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →